Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Non-Current Deffered Revenue: 2016-2018

Historic Non-Current Deffered Revenue for Anaptysbio (ANAB) over the last 2 years, with Dec 2018 value amounting to $171,000.

  • Anaptysbio's Non-Current Deffered Revenue rose 22.14% to $171,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $171,000, marking a year-over-year increase of 22.14%. This contributed to the annual value of $171,000 for FY2018, which is 22.14% up from last year.
  • According to the latest figures from Q4 2018, Anaptysbio's Non-Current Deffered Revenue is $171,000, which was up 5.56% from $162,000 recorded in Q3 2018.
  • In the past 5 years, Anaptysbio's Non-Current Deffered Revenue ranged from a high of $171,000 in Q4 2018 and a low of $128,000 during Q2 2018.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $154,000 (2016), whereas its average is $151,556.
  • Data for Anaptysbio's Non-Current Deffered Revenue shows a peak YoY increase of 22.14% (in 2018) and a maximum YoY decrease of 23.81% (in 2018) over the last 5 years.
  • Anaptysbio's Non-Current Deffered Revenue (Quarterly) stood at $154,000 in 2016, then decreased by 9.09% to $140,000 in 2017, then grew by 22.14% to $171,000 in 2018.
  • Its last three reported values are $171,000 in Q4 2018, $162,000 for Q3 2018, and $128,000 during Q2 2018.